Antibodies
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 16/813,167, filed Mar 9, 2020. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,008,399 | Antibodies In force · High confidence | Genmab A/S | In force | High confidence | ||
| US 11,130,819 | Antibodies In force · High confidence | Genmab A/S | In force | High confidence | ||
| US 11,970,544 | Antibodies In force · High confidence | Genmab A/S | In force | High confidence | ||
| Application 16/813,167 | Antibodies Abandoned Abandoned Jan 30, 2025 | Genmab A/S | Abandoned | Abandoned Jan 30, 2025 | ||
| Application 18/617,483 | Antibodies Pending Not granted | Genmab A/S | Pending | Not granted |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Genmab A/S.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.